跳至主要内容
临床试验/NCT00093652
NCT00093652终止1 期

ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates

Roswell Park Cancer Institute2 个研究点 分布在 1 个国家开始时间: 2003年5月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
试验地点
2
主要终点
Maximum tolerated dose (phase I)

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining oxaliplatin and gefitinib with radiation therapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of oxaliplatin when given together with gefitinib and radiation therapy and to see how well they work in treating patients with locally advanced or metastatic esophageal cancer.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of oxaliplatin when administered with gefitinib and radiotherapy in patients with locally advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction. (Phase I)
  • Determine the response rate in patients treated with this regimen. (Phase II)

Secondary

  • Determine time to tumor progression and median survival in patients treated with this regimen.
  • Determine quality of life in patients treated with this regimen.
  • Determine the safety of this regimen in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Maximum tolerated dose (phase I)

Response (phase II)

次要结局

  • Safety and toxicity
  • Immunohistochemistry
  • Survival
  • Quality of life

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验